

IL-17 RD

Catalog # PVGS1450

Product Information

| | |
|----------------------------------|--|
| Primary Accession Species | Q8JZL1-1 Mouse |
| Sequence | Gly28-Arg299 |
| Purity | > 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
| Endotoxin Level | |
| Biological Activity | ED ₅₀ |
| Expression System | CHO |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS. |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 µg/ml. |
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |

Additional Information

| | |
|--------------------------|--|
| Target Background | Interleukin-17 receptor D (IL-17RD) , also known as similar expression to the fibroblast growth factor receptor (SEF), is a member of the interleukin-17 receptor family. Studies indicate that IL-17RD interacts with IL-17R to facilitate IL-17 signaling. Additionally, IL-17RD may play an important role in preventing certain types of cancer. Studies suggest that IL-17D acts as a feedback inhibitor of fibroblast growth factor-mediated MAPK signaling and ERK activation. Studies indicate that IL-17D can bind to MEK/ERK complexes preventing nuclear ERK translocation and subsequent cell proliferation. |
|--------------------------|--|

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.